The development of this Guidelines video has been supported by an educational grant from Napp Pharmaceuticals Limited. Napp Pharmaceuticals Limited had no influence over the selection of the speaker or the content of the video, and checked the final files for technical accuracy only.

 

In November 2017, the Scottish Intercollegiate Guidelines Network (SIGN) published SIGN 154 on Pharmacological management of glycaemic control in people with type 2 diabetes. In this short video, Dr Kevin Fernando (GPwSI Diabetes and Medical Education) answers the following questions:

 

Further information:

Click here to view the Guidelines summary of Pharmacological management of glycaemic control in people with type 2 diabetes

View the full guideline at www.sign.ac.uk

References

  1. Scottish Intercollegiate Guidelines Network. SIGN 154: Pharmacological management of glycaemic control in people with type 2 diabetes. SIGN, 2017. www.sign.ac.uk/assets/sign154.pdf
  2. Scottish Intercollegiate Guidelines Network. SIGN 116: Management of diabetes. SIGN, 2010. www.sign.ac.uk/assets/sign116.pdf
  3. Neal B, Perkovic V, Mahaffey K et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644–657.
  4. Zinman B, Wanner C, Lachin J et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.
  5. Marso S, Daniels G, Brown-Frandsen K et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311–322.

The development of this Guidelines video has been supported by an educational grant from Napp Pharmaceuticals Limited. Napp Pharmaceuticals Limited had no influence over the selection of the speaker or the content of the video, and checked the final files for technical accuracy only. At all times editorial control has remained with the presenter and MGP.